Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company.


GlobeNewswire Inc | Oct 14, 2021 09:00AM EDT

October 14, 2021

WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7683407. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.

A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 7683407. The replay will be available for one week after the conference call.

About NeuroMetrix

NeuroMetrixis an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheckis a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCEis a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quellis a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial Officerneurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.









Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC